

## Stannyl Radical-Mediated Cleavage of $\pi$ -Deficient Heterocyclic Sulfones. Synthesis of $\alpha$ -Fluoro Esters and the First Homonucleoside $\alpha$ -Fluoromethylene Phosphonate<sup>1</sup>

Stanislaw F. Wnuk and Morris J. Robins\*

Department of Chemistry and Biochemistry  
Brigham Young University, Provo, Utah 84602-5700

Received October 19, 1995

Phosphonate derivatives of nucleosides have been studied extensively as analogues of biologically important nucleotides.<sup>2,3</sup> Blackburn proposed that  $\alpha$ -fluoro and  $\alpha,\alpha$ -difluoro substitution on methylenephosphonates should provide superior phosphate ester surrogates (closer isosteric and isopolar parallels).<sup>3,4</sup> The bridging oxygen in di- and triphosphates has been replaced with mono- and difluoromethylene entities,<sup>3–5</sup> and the OH function on phosphates has been replaced with a fluoromethyl group.<sup>6</sup> Condensations of O5'-activated nucleosides<sup>5a</sup> and activated 5'-monophosphates<sup>4a</sup> with (fluoromethylene)- and (difluoromethylene)bis(phosphonic acids) have given di- and triphosphate analogues with  $\alpha$  and  $\beta$  pyrophosphate oxygen replaced with CHF and CF<sub>2</sub> units. Phosphonate homologues of nucleotides (O5' replaced with CH<sub>2</sub>,<sup>7</sup> CHF,<sup>8</sup> or CF<sub>2</sub><sup>9</sup>) are of enhanced interest since they are not substrates for the usual phosphatases. Established syntheses of homophosphonates with CH<sub>2</sub> units employed Wittig<sup>7</sup> or Arbuzov<sup>2</sup> chemistry. Recent reports<sup>9,10</sup> of their CF<sub>2</sub> analogues have utilized coupling of nucleic acid bases with a previously synthesized  $\alpha,\alpha$ -difluorohomoribose phosphonate derivative<sup>11</sup> or a carbocyclic analogue.<sup>10</sup> The 9-(5,5-difluoro-5-phosphonopentyl)guanine congener of acyclovir phosphate was found to exert potent inhibition of purine nucleoside phosphorylase.<sup>12</sup>

$\alpha$ -Fluoro- and  $\alpha,\alpha$ -difluoromethylenephosphonates have been prepared by Arbuzov reactions with fluorohalomethanes,<sup>13</sup> fluorination of phosphonate-stabilized anions,<sup>14</sup> alkylation of [(diethoxyphosphoryl)difluoromethyl]lithium,<sup>15</sup> and palladium-catalyzed addition of diethyl (difluoroiodomethyl)phosphonate to alkenes.<sup>16</sup> Fluorinations of sulfonyl-stabilized phosphonate carbanions with perchloryl fluoride<sup>17</sup> and the new Selectfluor reagent<sup>18</sup> have been described. We employed Barton's chain-extension method with diethyl vinylphosphonate and a protected

uridine 5'-thiohydroxamic ester to obtain the 6'-(pyridin-2-yl) thioether. Its oxidation (*m*-CPBA) and fluorination of the derived sulfonyl-stabilized carbanion (Selectfluor) were successful. However, attempted desulfonylation by known procedures failed. We now have discovered that pyridin-2-yl- and especially pyrimidin-2-ylsulfonyl groups undergo cleavage from the  $\alpha$ -carbon atoms of carboxylic and phosphonic esters. This new methodology was employed for the first reported synthesis of a 6'-deoxy-6'-fluorohomonucleoside phosphonate from uridine.

Treatment of 2',3'-*O*-isopropylideneuridine 5'-carboxylic acid<sup>19</sup> (**1**, Scheme 1) with isobutyl chloroformate/*N*-methylmorpholine/THF and the sodium salt of *N*-hydroxypyridine-2-thione gave the *N*-hydroxypyridine-2-thioester. Photolysis (tungsten light) with diethyl vinylphosphonate gave the reported addition product **2**<sup>20a,b</sup> (~60%) plus byproducts.<sup>20c,d</sup> Attempted C6' fluorination of thioether **2** with (diethylamino)sulfur trifluoride (DAST)<sup>21a</sup> or oxidation of **2** and treatment of the sulfoxides with DAST/SbCl<sub>3</sub><sup>21b</sup> failed. Oxidation of **2** with >2 equiv of *m*-CPBA gave the pyridin-2-yl sulfone **3a**, which was benzooylated at N3 to give **3b**.<sup>22</sup> Treatment of **3b** with potassium hydride generated a stabilized C6' carbanion. Several "positive fluorine" sources failed to give defined products, but Selectfluor [1-(chloromethyl)-4-fluoro-1,4-diazabicyclo[2.2.2]octane bis-

(18) Lal, G. S. *J. Org. Chem.* **1993**, *58*, 2791–2796.

(19) (a) Corey, E. J.; Samuelsson, B. *J. Org. Chem.* **1984**, *49*, 4735–4735. (b) Varma R. S.; Hogan, M. E. *Tetrahedron Lett.* **1992**, *33*, 7719–7720.

(20) (a) Barton, D. H. R.; Géro, S. D.; Quiclet-Sire, B.; Samadi, M. *J. Chem. Soc., Chem. Commun.* **1989**, 1000–1001. (b) Barton, D. H. R.; Géro, S. D.; Quiclet-Sire, B.; Samadi, M. *Tetrahedron* **1992**, *48*, 1627–1636. (c) Barton, D. H. R.; Géro, S. D.; Quiclet-Sire, B.; Samadi, M. *J. Chem. Soc., Chem. Commun.* **1988**, 1372–1373. (d) Complete stereoselectivity<sup>20c</sup> for C5' modified nucleosides<sup>20a,b</sup> has been noted, but **2** was contaminated (5–15%) by compound(s) with similar NMR signals. A 4'(S) diastereomer should undergo parallel transformations to give parallel byproducts observed at each stage.

(21) (a) Robins, M. J.; Wnuk, S. F. *J. Org. Chem.* **1993**, *58*, 3800–3801. (b) Wnuk, S. F.; Robins, M. J. *J. Org. Chem.* **1990**, *55*, 4757–4760.

(22) NMR (CDCl<sub>3</sub>, unless specified). (a) Data as reported for **8c**<sup>23a</sup> and **10c**.<sup>23b</sup> (b) **3b**: <sup>1</sup>H NMR  $\delta$  1.25 (t, *J* = 7.0 Hz, 6), 1.31 (s, 3), 1.52 (s, 3), 2.40–2.71 (m, 2), 4.10 (q, *J* = 7.0 Hz, 4), 4.38–4.71 (m, 3), 4.96–5.12 (m, 1), 5.58 (d, *J* = 1.1 Hz, 0.5, H1'), 5.67 (d, *J* = 1.5 Hz, 0.5, H1'), 5.83 and 5.85 (d and d, *J* = 8.1 Hz, 0.5 and 0.5), 7.37 and 7.39 (d and d, 0.5 and 0.5), 7.45–8.14 (m, 8), 8.67–8.94 (m, 1); HRMS (CI) *m/z* 664.1724 (100, MH<sup>+</sup> [C<sub>29</sub>H<sub>35</sub>N<sub>3</sub>O<sub>11</sub>PS] = 664.1730). (c) **4b**:  $\delta$  1.24–1.35 (m, 9), 1.51 and 1.52 (2s, 3), 2.71–3.06 (m, 2), 4.16–4.32 (m, 4), 4.68–4.76 (m, 2), 4.96 (dd, *J*<sub>2'-3'</sub> = 6.3 Hz, *J*<sub>2'-1'</sub> = 2.0 Hz, 0.5, H2'), 4.99 (dd, *J*<sub>2'-3'</sub> = 5.9 Hz, *J*<sub>2'-1'</sub> = 2.0 Hz, 0.5, H2'), 5.48 and 5.49 (2d, 1, H1'), 5.68 and 5.71 (2dd, *J*<sub>5-6</sub> = 8.2 Hz, *J*<sub>5-NH</sub> = 2.3 Hz, 1, H5), 7.19 and 7.22 (2d, 1, H6), 7.60, 7.97, 8.14, 8.79 (4m, 4), 9.06 (br s, 1); <sup>19</sup>F NMR  $\delta$  -168.2 (ddd, *J*<sub>F-P</sub> = 82.2 Hz, *J*<sub>F-5',5''</sub> = 30.0, 17.1 Hz, 0.5), -168.6 (ddd, *J*<sub>F-P</sub> = 82.2 Hz, *J*<sub>F-5',5''</sub> = 29.1, 17.1 Hz), plus minor 4'(S) signals; HRMS (CI) *m/z* 578.1367 (100, MH<sup>+</sup> [C<sub>22</sub>H<sub>30</sub>FN<sub>3</sub>O<sub>10</sub>PS] = 578.1374). (d) **5b** (faster isomer): <sup>1</sup>H NMR (D<sub>2</sub>O)  $\delta$  1.23 (t, *J* = 6.9 Hz, 6), 2.22–2.36 (m, 2), 4.03 (t, *J* = 5.9 Hz, 1), 4.08–4.12 (m, 1), 4.15 (q, 4), 4.27 (t, *J* = 3.9 Hz, 1), 5.14 (dm, *J*<sub>6'-F</sub> = 45.2 Hz, 1), 5.67 (d, *J*<sub>1'-2'</sub> = 3.3 Hz, 1), 5.76 (d, *J*<sub>5-6</sub> = 8.2 Hz, 1), 7.52 (d, 1); <sup>19</sup>F NMR (D<sub>2</sub>O)  $\delta$  -203.2 (dddd, *J*<sub>F-P</sub> = 78.2 Hz, *J*<sub>F-6'</sub> = 46.1 Hz, *J*<sub>F-5',5''</sub> = 28.3, 10.5 Hz); HRMS (CI) *m/z* 397.1170 (100, MH<sup>+</sup> [C<sub>14</sub>H<sub>23</sub>FN<sub>3</sub>O<sub>8</sub>P] = 397.1176). (e) **6** (from faster **5b**): mp 200–210 °C dec; UV (H<sub>2</sub>O) max 262 nm ( $\epsilon$  8200), min 231 nm ( $\epsilon$  2100); <sup>1</sup>H NMR (D<sub>2</sub>O)  $\delta$  2.11–2.22 (m, 2), 4.04 (t, *J* = 6.0 Hz, 1), 4.15 (q, *J* = 6.2 Hz, 1), 4.25 (t, *J* = 5.0 Hz, 1), 4.83 (dm *J*<sub>6'-F</sub>  $\approx$  46 Hz, 1), 5.75 (d, *J*<sub>1'-2'</sub> = 4.5 Hz, 1), 5.88 (d, *J*<sub>5-6</sub> = 8.0 Hz, 1), 7.59 (d, 1); <sup>19</sup>F NMR (NaH/D<sub>2</sub>O)  $\delta$  -200.5 (dddd, *J*<sub>F-P</sub> = 61.9 Hz, *J*<sub>F-6'</sub> = 48.2 Hz, *J*<sub>F-5',5''</sub> = 27.3, 9.1 Hz); HRMS (FAB) *m/z* 385.0194 (76, MH<sup>+</sup> [C<sub>10</sub>H<sub>14</sub>FN<sub>2</sub>O<sub>8</sub>PN<sub>2</sub>] = 385.0189), 363.0370 (35, MH<sup>+</sup> [C<sub>10</sub>H<sub>14</sub>FN<sub>2</sub>O<sub>8</sub>PN<sub>2</sub>] = 363.0370). (f) **8a** (oil): <sup>1</sup>H NMR similar to **8b**. Anal. Calcd for C<sub>13</sub>H<sub>16</sub>NO<sub>4</sub>S: C, 54.72; H, 6.71; N, 4.91. Found: C, 54.63; H, 6.52; N, 5.09. (g) **8b**: mp 50–51 °C; <sup>1</sup>H NMR  $\delta$  0.90 (t, *J* = 6.6 Hz, 3), 1.1 (t, *J* = 7.1 Hz, 3), 1.28–1.51 (m, 4), 2.15–2.28 (m, 2), 4.10 (q, 2), 4.61 (dd, *J* = 6.2, 8.7 Hz, 1), 7.60 (t, *J* = 4.9 Hz, 1), 8.97 (d, 2). Anal. Calcd for C<sub>12</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub>S: C, 50.33; H, 6.34; N, 9.78. Found: C, 50.33; H, 6.15; N, 9.60. (h) **9a** (oil): <sup>1</sup>H NMR  $\delta$  0.90 (t, *J* = 6.8 Hz, 3), 1.16–1.52 (m, 7), 2.30–2.73 (m, 2), 4.31 (q, *J* = 7.2 Hz, 2), 7.60 (ddd, *J* = 1.4, 4.7, 7.6 Hz, 1), 7.98 (dt, *J* = 1.7, 7.6 Hz, 1), 8.09 (dt, *J* = 1.1 Hz, 7.8 Hz, 1), 8.73 (ddd, *J* = 1.0, 1.7, 4.8 Hz, 1); <sup>19</sup>F NMR  $\delta$  -159.4 (dd, *J* = 10.3, 38.5 Hz). Anal. Calcd for C<sub>13</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>4</sub>S: C, 51.47; H, 5.98; N, 4.62. Found: C, 51.39; H, 6.12; N, 4.51. (i) **9b** (oil): <sup>1</sup>H and <sup>19</sup>F NMR similar to **9a**. Anal. Calcd for C<sub>12</sub>H<sub>17</sub>FN<sub>2</sub>O<sub>4</sub>S: C, 47.36; H, 5.63; N, 9.20. Found: C, 47.57; H, 5.72; N, 9.19. (j) 2-[<sup>2</sup>H]-**10c**: <sup>1</sup>H NMR same as **10c**<sup>23b</sup> except simplification at  $\delta$  1.87 and small signals (~10%) at  $\delta$  4.86; <sup>19</sup>F NMR  $\delta$  -193.2 (tt, *J*<sub>F-D</sub> = 7.9 Hz, *J*<sub>F-H</sub> = 24.9 Hz).

(23) (a) Wang, Y.; Jiang, Y. *Synth. Commun.* **1992**, *22*, 2287–2291. (b) Thenappan, A.; Burton, D. J. *J. Org. Chem.* **1990**, *55*, 2311–2317.

(1) Nucleic Acid Related Compounds, 89, Part 88: Robins, M. J.; Wilson, J. S.; Madej, D.; Low, N. H.; Hansske, F.; Wnuk, S. F. *J. Org. Chem.* **1995**, *60*, 7902–7908.

(2) Engel, R. *Chem. Rev.* **1977**, *77*, 349–367.

(3) Blackburn, G. M.; Perrée, T. D.; Rashid, A.; Bisbal, C.; Lebleu, B. *Chem. Scr.* **1986**, *26*, 21–24.

(4) (a) Blackburn, G. M.; Kent, D. E.; Kolkman, F. *J. Chem. Soc., Perkin Trans. 1* **1984**, 1119–1125. (b) Blackburn, G. M.; Guo, M.-J.; Langston, S. P.; Taylor, G. E. *Tetrahedron Lett.* **1990**, *31*, 5637–5640. (c) Blackburn, G. M.; Langston, S. P. *Tetrahedron Lett.* **1991**, *32*, 6425–6428.

(5) (a) Davisson, V. J.; Davis, D. R.; Dixit, V. M.; Poulter, C. D. *J. Org. Chem.* **1987**, *52*, 1794–1801. (b) Hebel, D.; Kirk, K. L.; Kinjo, J.; Kovács, T.; Lesiak, K.; Balzarini, J.; De Clercq, E.; Torrence, P. F. *Bioorg. Med. Chem. Lett.* **1991**, *1*, 357–360.

(6) (a) Casara, P. J.; Jund, K. C.; Clauss, A.; Navé, J.-F.; Snyder, R. D. *Bioorg. Med. Chem. Lett.* **1992**, *2*, 145–148. (b) Blackburn, G. M.; Guo, M.-J. *Tetrahedron Lett.* **1993**, *34*, 149–152.

(7) Jones, G. H.; Moffatt, J. G. *J. Am. Chem. Soc.* **1968**, *90*, 5337–5338.

(8) Synthesis of monofluoro phosphonate analogues from a sugar precursor was presented by Blackburn et al.,<sup>3</sup> but no final products were reported.

(9) (a) Matulic-Adamic, J.; Usman, N. *Tetrahedron Lett.* **1994**, *35*, 3227–3230. (b) Matulic-Adamic, J.; Haerberli, P.; Usman, N. *J. Org. Chem.* **1995**, *60*, 2563–2569.

(10) Wolff-Kugel, D.; Halzay, S. *Tetrahedron Lett.* **1991**, *32*, 6341–6344.

(11) Berkowitz, D. B.; Eggen, M.-J.; Shen, Q.; Sloss, D. G. *J. Org. Chem.* **1993**, *58*, 6174–6176.

(12) Halazy, S.; Ehrhard, A.; Danzin, C. *J. Am. Chem. Soc.* **1991**, *113*, 315–317.


(13) Burton, D. J.; Flynn, R. M. *J. Fluorine Chem.* **1977**, *10*, 329–332.

(14) Differding, E.; Duthaler, R. O.; Krieger, A.; Rüegg, G. M.; Schmitz, C. *Synlett* **1991**, 395–396.

(15) Obayashi, M.; Ito, E.; Matsui, K.; Kondo, K. *Tetrahedron Lett.* **1982**, *23*, 2323–2326.

(16) Yang, Z.-Y.; Burton, D. J. *J. Org. Chem.* **1992**, *57*, 4676–4683.

(17) Koizumi, T.; Hagi, T.; Horie, Y.; Takeuchi, Y. *Chem. Pharm. Bull.* **1987**, *35*, 3959–3962.

Scheme 1<sup>a</sup>


<sup>a</sup> (a) (i) Isobutyl chloroformate/*N*-methylmorpholine/THF; (ii) sodium salt of *N*-hydroxy-pyridine-2-thione; (iii) diethyl vinylphosphonate/*hν*. (b) *m*-CPBA. (c) BzCl/EtN(*i*-Pr)<sub>2</sub>/pyridine. (d) KH/THF/Selectfluor/DMF. (e) NH<sub>3</sub>/MeOH. (f) Bu<sub>3</sub>SnH/AIBN/benzene/Δ. (g) TFA/H<sub>2</sub>O. (h) (i) Me<sub>3</sub>SiBr/DMF; (ii) DEAE Sephadex; (iii) Dowex 50 × 8(H<sup>+</sup>) then (Na<sup>+</sup>).

(tetrafluoroborate)]<sup>18</sup> gave the desired α-fluoro sulfone phosphonate **4a**, which was debenzoylated and purified to give **4b**<sup>22</sup> (47% from **3b**).

Standard procedures<sup>24</sup> for removal of sulfonyl groups [*e.g.*, treatment of **4b** with Al(Hg) or Na(Hg); or base-promoted elimination<sup>24b-d</sup>] failed to give **5a** or its 5',6'-unsaturated analogue. Although tributylstannane is used routinely for hydrolysis of carbon-halogen, carbon-sulfur, carbon-selenium, and carbon-nitro bonds,<sup>25</sup> it is ineffective for cleavage of typical saturated sulfones. In contrast, stannodesulfonylations of vinyl sulfones<sup>26</sup> (including nucleoside examples<sup>26b,c</sup>) are known, and recent desulfonylations of 2-(alkyl- and -aryl)sulfonylpyrroles<sup>27</sup> might involve successive stannodesulfonylation/protiodestannylation at the "vinyl" C2-C3 bond of the pyrrole ring. Desulfonylations of allylic sulfones<sup>28</sup> with tributylstannane are known, and sulfonyl radicals are versatile intermediates in organic synthesis.<sup>29</sup> Therefore, we began an investigation of radical-mediated cleavage of π-deficient aryl sulfones.

Ethyl hexanoate was chosen as a model for diethyl alkylphosphonates in which C2 would simulate the phosphonate α-carbon. Treatment of ethyl 2-bromohexanoate (**7**, Scheme 2) with pyridine-2-thione, pyrimidine-2-thione, and benzenethiol in solutions of NaH/THF/DMF gave the respective ethyl 2-(aryltio)hexanoates in excellent yields. Oxidation gave the corresponding sulfones **8a,b**<sup>22</sup> and **8c**.<sup>23a</sup> Treatment of ethyl 2-(phenylsulfonyl)hexanoate (**8c**) with Bu<sub>3</sub>SnH/AIBN/benzene

## Scheme 2



at reflux for 48 h caused no observed change in the starting material. However, parallel treatment of ethyl 2-(pyridin-2-ylsulfonyl)hexanoate (**8a**) for 36 h gave ethyl hexanoate (**10a**, 60%) plus unchanged **8a** and minor decomposition products. Analogous treatment of ethyl 2-(pyrimidin-2-ylsulfonyl)hexanoate (**8b**) gave complete conversion to **10a** within 1 h. Substitution of Bu<sub>3</sub>SnD for Bu<sub>3</sub>SnH gave ethyl 2-deuteriohexanoate (**10b**).

Carbanion-mediated fluorinations proceeded smoothly in the model series. The 2-(pyridin-2-ylsulfonyl) **8a** and 2-(pyrimidin-2-ylsulfonyl) **8b** esters were treated with potassium hydride, and the enolates were quenched with Selectfluor to give ethyl 2-fluoro-2-(pyridin-2-ylsulfonyl)hexanoate<sup>22</sup> (**9a**) and ethyl 2-fluoro-2-(pyrimidin-2-ylsulfonyl)hexanoate<sup>22</sup> (**9b**) in high yields. Tributylstannane-mediated desulfonylation of **9a** (28 h) and **9b** (1 h) gave ethyl 2-fluorohexanoate<sup>23b</sup> (**10c**; 60% and 95%, respectively). Treatment of **9b** with Bu<sub>3</sub>SnD gave 2-[<sup>2</sup>H]-**10c**.<sup>22</sup> These reactions<sup>30</sup> provide convenient access to biologically important α-fluorocarbonyl compounds<sup>31</sup> and their isotope-labeled derivatives. π-Deficient heterocyclic sulfones could be especially advantageous in reactions that involve generation of sulfonyl carbanions since acidifying effects of these pyridin- and pyrimidin-2-ylsulfonyl groups on α-carbon are greater than that of the phenylsulfonyl group.

This methodology for sulfone removal was successful for the synthesis of our target nucleoside phosphonate. Treatment of **4b** with Bu<sub>3</sub>SnH/AIBN/benzene/Δ/48 h caused cleavage of the sulfonyl linkage (**5a**, 61%), and removal of the isopropylidene group and RP-HPLC (H<sub>2</sub>O/CH<sub>3</sub>CN; 19:1) gave pooled fractions of **5b**<sup>22</sup> enriched in each of the two 6'-fluoro diastereomers (~12:1 *vs* ~1:6). Independent treatment of the enriched diastereomer mixtures with trimethylsilyl bromide and purification (DEAE Sephadex A-25; 0.01 → 0.20 M TEAB/H<sub>2</sub>O) followed by conversion to the sodium salts [Dowex 50 × 8(H<sup>+</sup>) and then (Na<sup>+</sup>); H<sub>2</sub>O] gave 6'-deoxy-6'-fluoro-6'-(phosphonato)-homouridine disodium salt<sup>22</sup> (**6**).

In summary, we have developed convenient and efficient methodologies for synthesis of carboxylate and phosphonate heterocyclic α-sulfones, their α-fluorination with Selectfluor, and their desulfonylation with tributylstannane. This provides a facile new route for the preparation of α-[<sup>2,3</sup>H] and α-fluoro-α-[<sup>2,3</sup>H] carbonyl compounds and phosphonates. Barton thiohydroxamic ester chemistry was used to prepare a protected 6'-(pyridin-2-ylthio)homouridine phosphonate that was oxidized (*m*-CPBA) to the sulfone, fluorinated (Selectfluor), desulfonylated (Bu<sub>3</sub>SnH/AIBN), and deprotected to give the first reported 6'-deoxy-6'-fluorohomonucleoside 6'-phosphonate.

**Acknowledgment.** We thank the American Cancer Society (Grant DHP-34) and Brigham Young University development funds for support, Air Products for a gift of Selectfluor reagent, and Mrs. Jeanny Gordon for assistance with the manuscript. We also thank Professor Stefan Kinastowski and the Academy of Agriculture, Poznan, Poland, for extensions of a faculty leave for S.F.W.

(24) (a) Simpkins, N. S. *Sulphones in Organic Synthesis*; Pergamon Press: Oxford, 1993. (b) Fuchs, P. L.; Braish, T. F. *Chem. Rev.* **1986**, *86*, 903-917. (c) Van Dort, P. C.; Fuchs, P. L. *J. Am. Chem. Soc.* **1994**, *116*, 5657-5661. (d) Jin, Z.; Vandort, P. C.; Fuchs, P. L. *Phosphorus, Sulfur Silicon Relat. Elem.* **1994**, *95*-96, 1-19.

(25) (a) Neumann, W. P. *Synthesis* **1987**, 665-683. (b) Pereyre, M.; Quintard, J.-P.; Rahm, A. *Tin in Organic Synthesis*; Butterworths: London, 1987.

(26) (a) Watanabe, Y.; Ueno, Y.; Araki, T.; Endo, T.; Okawara, M. *Tetrahedron Lett.* **1986**, *27*, 215-218. (b) McCarthy, J. R.; Matthews, D. P.; Stemerick, D. M.; Huber, E. W.; Bey, P.; Lippert, B. J.; Snyder, R. D.; Sunkara, P. S. *J. Am. Chem. Soc.* **1991**, *113*, 7439-7440. (c) Wnuk, S. F.; Yuan, C.-S.; Borchardt, R. T.; Balzarini, J.; De Clercq, E.; Robins, M. J. *J. Med. Chem.* **1994**, *37*, 3579-3587.

(27) Antonio, Y.; De La Cruz, M. E.; Galeazzi, E.; Guzman, A.; Bray, B. L.; Greenhouse, R.; Kurz, L. J.; Lustig, D. A.; Maddox, M. L.; Muchowski, J. M. *Can. J. Chem.* **1994**, *72*, 15-22.

(28) Ueno, Y.; Aoki, S.; Okawara, M. *J. Am. Chem. Soc.* **1979**, *101*, 5414-5415.

(29) Bertrand, M. P. *Org. Prep. Proced. Int.* **1994**, *26*, 257-290.

(30) Typical procedure: Ar was bubbled through **9b** (304 mg, 1 mmol)/benzene (5 mL) for 1 h, and Bu<sub>3</sub>SnH (0.537 mL, 582 mg, 2.0 mmol) was added. Deoxygenation was continued for 15 min, AIBN (33 mg, 0.2 mmol) was added, and the solution was refluxed for 1 h (TLC). Volatiles were evaporated (<25 °C, ~20 mmHg) and the residue was stirred overnight with EtOAc/KF/H<sub>2</sub>O (5 mL/30 mg/0.3 mL). The mixture was evaporated, and the residue was chromatographed (silica, pentane → 3% EtOAc/pentane) to give **10c**<sup>23b</sup> (154 mg, 95%).

(31) Rozen, S.; Filler, R. *Tetrahedron* **1985**, *41*, 1111-1153.